Raleigh biotech launched with $60M. A year later, it’s shut down


A Raleigh company has folded less than a year after launching with tens of millions in financial backing and a goal to turn psychedelics into a treatment for depression.

Previous Kansas City-area banks see local deposits set a 15-year high, but outside deposits shrink
Next Truist trims board size as former CEO Kelly King, HPU's Nido Qubein, others to depart at end of year